Prostatitis

NIH Study Initiated To Help Unravel Mysterious Condition

Published in Medical Letter on the CDC and FDA, January 13th, 2002

Boehringer Ingelheim Pharmaceuticals, Inc., announced its involvement in the initiation of a U.S. National Institutes of Health (NIH) clinical trial on prostatitis, a pervasive and painful condition that impacts millions of men.

The NIH decision to pursue this clinical research is significant because prostatitis, while affecting 50% of all men during their lifetime, is not well understood or studied, leading to difficulty diagnosing and treating the condition. The NIH multisite, double-blind, placebo-controlled, randomized study is the first designed to evaluate the efficacy, safety, and tolerability of an alpha-blocker (Flomax, tamsulosin HCL) and an oral antibiotic...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2002-01-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry